<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2072-0351-5662</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-5662</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Роль статинов в коррекции диабетической дислипидемии</article-title><trans-title-group xml:lang="en"><trans-title>Rol' statinov v korrektsii diabeticheskoy dislipidemii</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Доборджгинидзе</surname><given-names>Л М</given-names></name><name name-style="western" xml:lang="en"><surname>Dobordzhginidze</surname><given-names>L M</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грацианский</surname><given-names>Николай Андреевич</given-names></name><name name-style="western" xml:lang="en"><surname>Gratsianskiy</surname><given-names>Nikolay Andreevich</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>НИИ Физико-химической медицины Минздрава Российской Федерации, Москва</institution></aff><pub-date pub-type="collection"><year>2001</year></pub-date><pub-date pub-type="epub"><day>15</day><month>06</month><year>2001</year></pub-date><volume>4</volume><issue>2</issue><issue-title>№2 (2001)</issue-title><fpage>41</fpage><lpage>47</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Доборджгинидзе Л.М., Грацианский Н.А., 2001</copyright-statement><copyright-year>2001</copyright-year><copyright-holder xml:lang="ru">Доборджгинидзе Л.М., Грацианский Н.А.</copyright-holder><copyright-holder xml:lang="en">Dobordzhginidze L.M., Gratsianskiy N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/5662">https://www.dia-endojournals.ru/jour/article/view/5662</self-uri><abstract><p>Необходимость коррекции дислипидемии у больных с диабетом основывается на следующих фактах: диабет широко распространен, а сердечно-сосудистые заболевания - основная причина смерти больных с сахарным диабетом. Высокая частота ИБС среди больных с сахарным диабетом ясно указывает на необходимость модификации риска для того, чтобы снизить главную причину заболеваемости и смертности у данной категории больных. Контроль за уровнем глюкозы не позволяет снизить смертность больных с диабетом. Результаты крупных клинических исследований с применением статинов указывают на безопасность и эффективность гиполипидемической терапии у больных с диабетом не только относительно уровня и состава липидов, но и в отношении клинические исходов (кардиальная и общая смертность), при этом благоприятный эффект статинов у больных с диабетом даже выше, чем у лиц не страдающих диабетом.</p></abstract><kwd-group xml:lang="ru"><kwd>статины</kwd><kwd>диабетическая дислипидемия</kwd><kwd>сахарный диабет</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Stamler J., Vaccaro О., Neaton DJ et al. Diabetes Care 1 993; 16: 434444).</mixed-citation><mixed-citation xml:lang="en">Stamler J., Vaccaro О., Neaton DJ et al. Diabetes Care 1 993; 16: 434444).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kannel W.B., Me Gree D.L. JAMA 1979,241:2035-2038.</mixed-citation><mixed-citation xml:lang="en">Kannel W.B., Me Gree D.L. JAMA 1979,241:2035-2038.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association. Diabetes 1 996 Vital Statistics. Chicago: American Diabetes Association, 1 996:29.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association. Diabetes 1 996 Vital Statistics. Chicago: American Diabetes Association, 1 996:29.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes association: detection and management of lipid disorders in Diabetes. Diabetes Care 1993; 16(suppl 2):106.</mixed-citation><mixed-citation xml:lang="en">American Diabetes association: detection and management of lipid disorders in Diabetes. Diabetes Care 1993; 16(suppl 2):106.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ritter L, Troelsen S, Beck-Nielsen H. Diabetes Care 1 985;8:230-234.</mixed-citation><mixed-citation xml:lang="en">Ritter L, Troelsen S, Beck-Nielsen H. Diabetes Care 1 985;8:230-234.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Silva JA, Escobar A, Collins TJ et al. Circulation 1995; 92: 1731-1736.</mixed-citation><mixed-citation xml:lang="en">Silva JA, Escobar A, Collins TJ et al. Circulation 1995; 92: 1731-1736.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fava S, Azzopardi J, Agius-Muscat H. Diab Med 1997;14:209-213.</mixed-citation><mixed-citation xml:lang="en">Fava S, Azzopardi J, Agius-Muscat H. Diab Med 1997;14:209-213.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lehto S, Pyorala K, Miettinen H et al. J Int Med 1994;236:291-297.</mixed-citation><mixed-citation xml:lang="en">Lehto S, Pyorala K, Miettinen H et al. J Int Med 1994;236:291-297.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sprafka JM, Burke GL, Folsom AR et al. Diabetes Care 1991;14(7):537543.</mixed-citation><mixed-citation xml:lang="en">Sprafka JM, Burke GL, Folsom AR et al. Diabetes Care 1991;14(7):537543.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Haffner SM, Lehto S, Ronnemaa T et al. New Engl J Med 1998;339:229-234.</mixed-citation><mixed-citation xml:lang="en">Haffner SM, Lehto S, Ronnemaa T et al. New Engl J Med 1998;339:229-234.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gustafsson I, Hildebrandt P, Seibaeck et al. and the TRACE Study Group. Eur Heart J 2000;21:1937-1943.</mixed-citation><mixed-citation xml:lang="en">Gustafsson I, Hildebrandt P, Seibaeck et al. and the TRACE Study Group. Eur Heart J 2000;21:1937-1943.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Krolevski et al. Am J Cardiol 1987;59:750-755.</mixed-citation><mixed-citation xml:lang="en">Krolevski et al. Am J Cardiol 1987;59:750-755.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999,-22 (supll 1):S56-S59.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999,-22 (supll 1):S56-S59.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Krolewski AS, Kosinski EJ, Warram JH et al. Am J Cardiol 1993; 72:458-460.</mixed-citation><mixed-citation xml:lang="en">Krolewski AS, Kosinski EJ, Warram JH et al. Am J Cardiol 1993; 72:458-460.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Erkelens DW. Diabetic dyslipidaemia. Eur Heart J 1998; 19(suppl H): H27-H30.</mixed-citation><mixed-citation xml:lang="en">Erkelens DW. Diabetic dyslipidaemia. Eur Heart J 1998; 19(suppl H): H27-H30.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Laakso M, Lehto S, Pentilla I, Pyorala K. Circulation 1993;88:(part 1)1421-30.</mixed-citation><mixed-citation xml:lang="en">Laakso M, Lehto S, Pentilla I, Pyorala K. Circulation 1993;88:(part 1)1421-30.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab. 1999;25:199-211. 1 8. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.</mixed-citation><mixed-citation xml:lang="en">Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab. 1999;25:199-211. 1 8. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.</mixed-citation><mixed-citation xml:lang="en">UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">LaRosa JC. Unresolved issues in early trials of cholesterol lowering. Am J Cardiol 1995;76:5C-9C</mixed-citation><mixed-citation xml:lang="en">LaRosa JC. Unresolved issues in early trials of cholesterol lowering. Am J Cardiol 1995;76:5C-9C</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Pyorala K, Pedersen TR, Kjekshus J et al, for the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20(4):614-620.</mixed-citation><mixed-citation xml:lang="en">Pyorala K, Pedersen TR, Kjekshus J et al, for the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20(4):614-620.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Haffner SM, Alexander CM, Cook TJ et al. Arch Intern Med 1999;159:2661-2667.</mixed-citation><mixed-citation xml:lang="en">Haffner SM, Alexander CM, Cook TJ et al. Arch Intern Med 1999;159:2661-2667.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sacks FM, Pfeffer МА, Moye et al. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.</mixed-citation><mixed-citation xml:lang="en">Sacks FM, Pfeffer МА, Moye et al. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Goldberg RB, Mellies MJ, Sacks FM et al. Circulation 1998,98:25132519.</mixed-citation><mixed-citation xml:lang="en">Goldberg RB, Mellies MJ, Sacks FM et al. Circulation 1998,98:25132519.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Morse J. Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDL-C and diabetes mellitus or impaired fasting glucose (HATS). J Am Coll Cardiol 2001; Abstracts ACC Session,</mixed-citation><mixed-citation xml:lang="en">Morse J. Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDL-C and diabetes mellitus or impaired fasting glucose (HATS). J Am Coll Cardiol 2001; Abstracts ACC Session,</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bakker-Arkema R,G., Davidson M.H., Goldstein R.J., et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-133</mixed-citation><mixed-citation xml:lang="en">Bakker-Arkema R,G., Davidson M.H., Goldstein R.J., et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-133</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Stein EA, Lane M, Laskarzewsky P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66b-69b.</mixed-citation><mixed-citation xml:lang="en">Stein EA, Lane M, Laskarzewsky P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66b-69b.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Andrade SE, Walker AM, Gottlieb LK et al. N Engl J Med 1995;332:1125-1 131.</mixed-citation><mixed-citation xml:lang="en">Andrade SE, Walker AM, Gottlieb LK et al. N Engl J Med 1995;332:1125-1 131.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Pearson ТА, Laurora I, Cho H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and echieving low density low density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.</mixed-citation><mixed-citation xml:lang="en">Pearson ТА, Laurora I, Cho H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and echieving low density low density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ma P, Hegele R, Yale JF, Sshartz B. CAVEAT: a randomized, doubleblind, paralleled group evaluation of cerivastatin 0,4 mg and 0,8 mg compared to atorvastatin 1 Omg and 20 mg once daily in patients with combined (type Mb) dyslipidaemia. The British J of Cardiol 2000;7:780786.</mixed-citation><mixed-citation xml:lang="en">Ma P, Hegele R, Yale JF, Sshartz B. CAVEAT: a randomized, doubleblind, paralleled group evaluation of cerivastatin 0,4 mg and 0,8 mg compared to atorvastatin 1 Omg and 20 mg once daily in patients with combined (type Mb) dyslipidaemia. The British J of Cardiol 2000;7:780786.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">National Cholesterol Education Program Second Report of the Expert Pannel on Detection, Evolution and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89:1333-1440.</mixed-citation><mixed-citation xml:lang="en">National Cholesterol Education Program Second Report of the Expert Pannel on Detection, Evolution and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89:1333-1440.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000;39(2):99-l 16.</mixed-citation><mixed-citation xml:lang="en">Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000;39(2):99-l 16.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Muck W. Rationale assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998;56(suppll ):1523. '</mixed-citation><mixed-citation xml:lang="en">Muck W. Rationale assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998;56(suppll ):1523. '</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Stein E, Schopen U, Catagoy M. A pooled efficacy analysis of cerivastatin in the treatment of primary hyperlipidaemia. Clin Drug Invest 1999,18(6) 433-444.</mixed-citation><mixed-citation xml:lang="en">Stein E, Schopen U, Catagoy M. A pooled efficacy analysis of cerivastatin in the treatment of primary hyperlipidaemia. Clin Drug Invest 1999,18(6) 433-444.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">De Luis DA, Romero E, Izaola O. Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus. Clin Nutr 2000; 19(5):367-370.</mixed-citation><mixed-citation xml:lang="en">De Luis DA, Romero E, Izaola O. Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus. Clin Nutr 2000; 19(5):367-370.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Rubinstein A, Maritz FJ, Soule SG et al. Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolemia. Hyperlipidaemia in diabetes melitus investigators. J Cardiovasc Risk 1999; 6(6):399-403</mixed-citation><mixed-citation xml:lang="en">Rubinstein A, Maritz FJ, Soule SG et al. Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolemia. Hyperlipidaemia in diabetes melitus investigators. J Cardiovasc Risk 1999; 6(6):399-403</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
